Trends in acute myocardial infarction management: use of the national registry of myocardial infarction in quality improvement

Cardiovascular disease, including acute myocardial infarction (AMI), is the leading cause of death in the United States and was the primary disease category among hospital discharges in 1996. Efforts to improve hospital care of patients with AMI should be measured and assessed routinely for appropriateness of care and improvement of medical staff performance. The National Registry of Myocardial Infarction (NRMI), an observational Phase IV study, has enrolled >1 million AMI patients since 1990, and is now in its third phase. NRMI 3 collects patient data and facilitates the measurement of improvement in care and outcomes, while allowing participating institutions to benchmark their performance against national, state, and like-hospital data. Three measures from NRMI 3 are accepted for the Joint Commission on Accreditation of Healthcare Organizations’ ORYX initiative: (1) aspirin use within 24 hours of AMI diagnosis; (2) door-to-drug time for fibrinolysis; and (3) no initial reperfusion strategy given to eligible patients.